Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Bevacizumab--current status and future directions.

Midgley R, Kerr D.

Ann Oncol. 2005 Jul;16(7):999-1004. Epub 2005 Jun 6. Review.

PMID:
15939715
2.

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.

Curr Med Chem. 2006;13(16):1845-57. Review.

PMID:
16842197
3.

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

Shih T, Lindley C.

Clin Ther. 2006 Nov;28(11):1779-802. Review.

PMID:
17212999
4.

Technology evaluation: bevacizumab, Genentech/Roche.

Salgaller ML.

Curr Opin Mol Ther. 2003 Dec;5(6):657-67.

PMID:
14755893
5.

Bevacizumab in the treatment of colorectal cancer.

Mulcahy MF, Benson AB 3rd.

Expert Opin Biol Ther. 2005 Jul;5(7):997-1005. Review.

PMID:
16018743
6.

Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.

Grothey A, Ellis LM.

Cancer J. 2008 May-Jun;14(3):170-7. doi: 10.1097/PPO.0b013e318178d9de. Review.

PMID:
18536556
7.

Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.

Hsu JY, Wakelee HA.

BioDrugs. 2009;23(5):289-304. doi: 10.2165/11317600-000000000-00000. Review.

PMID:
19754219
8.

Bevacizumab: current indications and future development for management of solid tumors.

Jenab-Wolcott J, Giantonio BJ.

Expert Opin Biol Ther. 2009 Apr;9(4):507-17. doi: 10.1517/14712590902817817 . Review.

PMID:
19344286
9.

Expanding the clinical development of bevacizumab.

Chen HX.

Oncologist. 2004;9 Suppl 1:27-35. Review.

10.

Vascular biology support for the use of bevacizumab in colorectal cancer.

Doggrell SA.

Expert Opin Investig Drugs. 2004 Jun;13(6):703-5. Review.

PMID:
15174956
11.
12.

Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.

Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, Pronzato P, Grossi F.

Crit Rev Oncol Hematol. 2008 Dec;68(3):183-96. doi: 10.1016/j.critrevonc.2008.05.002. Epub 2008 Jul 7. Review.

PMID:
18606548
13.

Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

Jubb AM, Harris AL.

Lancet Oncol. 2010 Dec;11(12):1172-83. doi: 10.1016/S1470-2045(10)70232-1. Review.

PMID:
21126687
14.

Bevacizumab in the treatment of metastatic colorectal cancer.

Caprioni F, Fornarini G.

Future Oncol. 2007 Apr;3(2):141-8. Review.

PMID:
17381413
15.
16.

Bevacizumab in non small cell lung cancer.

Sandler A.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4613-6. Review.

17.

[Anti-VEGF therapy with bevacizumab in breast cancer].

Tóth J, Gonda A, Szántó J.

Lege Artis Med. 2008 Oct;18(10):669-73. Hungarian.

PMID:
19227609
18.

Angiogenesis inhibition in the treatment of lung cancer.

Vokes E, Herbst R, Sandler A.

Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 23):1-10; quiz 11-2. Review.

PMID:
17143257
19.

New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.

Manegold C.

Clin Lung Cancer. 2008;9 Suppl 3:S100-8. doi: 10.3816/CLC.2008.s.015. Review.

PMID:
19419923
20.

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.

Marty M, Pivot X.

Eur J Cancer. 2008 May;44(7):912-20. doi: 10.1016/j.ejca.2008.01.005. Epub 2008 Apr 7. Review.

PMID:
18396037

Supplemental Content

Support Center